An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

ClinicalTrials.gov ID: NCT06169397

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT06169397. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Long-term Multicenter Open-label Study to Evaluate the Long-term Safety and Durability of Effect of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extra-pulmonary Involvement

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Open-label Study to Evaluate the Long-term Safety and Durability of Effect of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extra-pulmonary Involvement

Study identification

NCT ID: NCT06169397
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Xentria, Inc.; Industry
Enrollment: 31 participants

Conditions and interventions

Conditions

Pulmonary Sarcoidosis

Interventions

XTMAB-16 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 80 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 1, 2024 (Actual)
Primary completion: Oct 9, 2026 (Actual)
Completion: Oct 9, 2026 (Actual)
Last update posted: Oct 16, 2026

2024 – 2026

United States locations

U.S. sites: 5
U.S. states: 5
U.S. cities: 5

Facility	City	State	ZIP	Site status
Xentria Investigative Site	Denver	Colorado	80206	—
Xentria Investigative Site	Chicago	Illinois	60611	—
Xentria Investigative Site	Greenville	North Carolina	27858	—
Xentria Investigative Site	Cincinnati	Ohio	45267	—
Xentria Investigative Site	Philadelphia	Pennsylvania	19140	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06169397, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 16, 2026 · Synced Nov 15, 2026